Bayesian single‐to‐double arm transition design using both short‐term and long‐term endpoints

Abstract

AbstractThe choice between single‐arm designs versus randomized double‐arm designs has been contentiously debated in the literature of phase II oncology trials. Recently, as a compromise, the single‐to‐double arm transition design was proposed, combining the two designs into one trial over two stages. Successful implementation of the two‐stage transition design requires a suspension period at the end of the first stage to collect the response data of the already enrolled patients. When the evaluation of the primary efficacy endpoint is overly long, the between‐stage suspension period may unfavorably prolong the trial duration and cause a delay in treating future eligible patients. To accelerate the trial, we propose a Bayesian single‐to‐double arm design with short‐term endpoints (BSDS), where an intermediate short‐term endpoint is used for making early termination decisions at the end of the single‐arm stage, followed by an evaluation of the long‐term endpoint at the end of the subsequent double‐arm stage. Bayesian posterior probabilities are used as the primary decision‐making tool at the end of the trial. Design calibration steps are proposed for this Bayesian monitoring process to control the frequentist operating characteristics and minimize the expected sample size. Extensive simulation studies have demonstrated that our design has comparable power and average sample size but a much shorter trial duration than conventional single‐to‐double arm design. Applications of the design are illustrated using two phase II oncology trials with binary endpoints.